The proposed study will investigate the effects of etelcalcetide on the bone and blood-vessel
health in patients with CKD-MBD. The investigators will test if etelcalcetide makes bone and
blood-vessels healthier. The study hypotheses are that are that etelcalcetide keeps bones
strong and lowers the risk of calcium deposits in blood vessels. In Aim 1, the investigators
will test if 9-months of treatment with etelcalcetide improves bone strength in twenty ESKD
patients with hyperparathyroidism (HPT) by bone biopsy. In Aim 2, the investigators will test
if 9-months of treatment with etelcalcetide decreases serum propensity to calcify blood
vessels. The potential significance of this study is to provide first-time data on the
ability of etelcalcetide to protect bone and blood-vessel health in patients with ESKD.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.